{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:31:57Z","timestamp":1790087517143,"version":"4.0.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>People with lower extremity peripheral artery disease (PAD) suffer from a high burden of symptoms and significant functional impairment. There are few therapies that improve function and reduce symptoms in this population. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to improve glycaemic control, reduce body weight, and reduce the risk of major adverse cardiovascular events in people with atherosclerotic cardiovascular disease and type 2 diabetes (T2D).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>STRIDE (NCT04560998) is a randomized, placebo-controlled, double-blind phase 3b trial evaluating 1\u00a0mg once-weekly subcutaneous semaglutide (GLP-1 RA) vs. placebo, in people with symptomatic PAD (Fontaine IIa claudication) and T2D. Eligible participants were \u226518 years, had haemodynamically stable PAD, had no planned intervention, and were not receiving a GLP-1 RA. The primary endpoint is change in maximum walking distance on a constant-load treadmill (CLT). Secondary endpoints include quality of life and cardiometabolic assessments. A total of 792 participants were randomized in 20 countries. Participants\u2019 median age was 68 and median T2D duration 12 years. Risk factors included 25.6% current smokers, 87.9% with hypertension, and 42.7% with coronary heart disease. The mean BMI was 29.6\u00a0kg\/m2 and the mean HbA1C was 7.3%. Participants exhibited baseline functional impairment with a median maximum walking distance of 186 m on a CLT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>STRIDE has enrolled participants with symptomatic PAD and T2D, frequent risk factors and comorbidities, and functional impairment. The trial will provide evidence for the functional outcomes with semaglutide in people with PAD and T2D.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvae071","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T02:20:20Z","timestamp":1729304420000},"page":"728-737","source":"Crossref","is-referenced-by-count":24,"title":["Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-3584","authenticated-orcid":false,"given":"Marc P","family":"Bonaca","sequence":"first","affiliation":[{"name":"CPC Clinical Research, Cardiovascular Division, University of Colorado School of Medicine , Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei-Mircea","family":"Catarig","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Hansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1600-4415","authenticated-orcid":false,"given":"Kim","family":"Houlind","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Lillebaelt Hospital"},{"name":"Department of Regional Health Research, University of Southern Denmark ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chethana Kalmady","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Novo Nordisk GBS India , Bangalore ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Ludvik","sequence":"additional","affiliation":[{"name":"1st Medical Department and Karl Landsteiner Institute for Obesity and Metabolic Disorders Landstrasse Clinic , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-2268","authenticated-orcid":false,"given":"Joakim","family":"Nordanstig","sequence":"additional","affiliation":[{"name":"Institute of Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1269-3580","authenticated-orcid":false,"given":"Neda","family":"Rasouli","sequence":"additional","affiliation":[{"name":"School of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado , Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-9594","authenticated-orcid":false,"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[{"name":"Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-8533","authenticated-orcid":false,"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Surgery, St. Michael's Hospital, University of Toronto , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"2025011107303453900_bib1","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2025011107303453900_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025011107303453900_bib3","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"key":"2025011107303453900_bib4","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.jacc.2022.02.031","article-title":"Impact of polyvascular disease and diabetes on limb and cardiovascular risk in peripheral artery disease","volume":"79","author":"Behan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025011107303453900_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCULATIONAHA.119.040672","article-title":"Microvascular disease, peripheral artery disease, and amputation","volume":"140","author":"Beckman","year":"2019","journal-title":"Circulation"},{"key":"2025011107303453900_bib6","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2023.09.830","article-title":"Disparities in diagnosis, treatment, and outcomes of peripheral artery disease: JACC scientific statement","volume":"82","author":"Mcdermott","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025011107303453900_bib7","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/dom.14700","article-title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","volume":"24","author":"Verma","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2025011107303453900_bib8","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025011107303453900_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"31","author":"Lingvay","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"2025011107303453900_bib10","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with Type 2 diabetes at high risk for cardiovascular events: results from the LEADER Trial","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"key":"2025011107303453900_bib11","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2025011107303453900_bib12","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of peripheral artery disease and polyvascular disease","volume":"128","author":"Aday","year":"2021","journal-title":"Circ Res"},{"key":"2025011107303453900_bib13","doi-asserted-by":"crossref","first-page":"znad413","DOI":"10.1093\/bjs\/znad413","article-title":"BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally","volume":"111","author":"Farber","year":"2024","journal-title":"Br J Surg"},{"key":"2025011107303453900_bib14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jvs.2023.12.027","article-title":"Discordance of patient-reported outcome measures with objectively assessed walking decline in peripheral artery disease","volume":"79","author":"Mcdermott","year":"2024","journal-title":"J Vasc Surg"},{"key":"2025011107303453900_bib15","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Writing Committee","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025011107303453900_bib16","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jacc.2008.09.063","article-title":"Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study)","volume":"53","author":"Mcdermott","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025011107303453900_bib17","doi-asserted-by":"crossref","first-page":"e007953","DOI":"10.1161\/CIRCOUTCOMES.121.007953","article-title":"Supervised exercise therapy for symptomatic peripheral artery disease among medicare beneficiaries between 2017 and 2018: participation rates and outcomes","volume":"14","author":"Divakaran","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025011107303453900_bib18","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1001\/archinte.159.17.2041","article-title":"A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial","volume":"159","author":"Beebe","year":"1999","journal-title":"Arch Intern Med"},{"key":"2025011107303453900_bib19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.CIR.98.7.678","article-title":"Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial","volume":"98","author":"Dawson","year":"1998","journal-title":"Circulation"},{"key":"2025011107303453900_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9343(00)00569-6","article-title":"A comparison of cilostazol and pentoxifylline for treating intermittent claudication","volume":"109","author":"Dawson","year":"2000","journal-title":"Am J Med"},{"key":"2025011107303453900_bib21","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2022.14912","article-title":"Telmisartan and walking performance in peripheral artery disease","volume":"328","author":"Bonaca","year":"2022","journal-title":"JAMA"},{"key":"2025011107303453900_bib22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacc.2022.08.754","article-title":"2022 ACC expert consensus decision pathway for integrating atherosclerotic cardiovascular disease and multimorbidity treatment: a framework for pragmatic, patient-centered care: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Writing Committee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025011107303453900_bib23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"key":"2025011107303453900_bib24","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/ATVBAHA.123.319156","article-title":"Presence of peripheral artery disease is associated with increased risk of heart failure events: insights from EMPEROR-Pooled","volume":"43","author":"Verma","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025011107303453900_bib25","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025011107303453900_bib26","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1161\/CIRCULATIONAHA.124.069449","article-title":"Stepping into the future of care for patients with PAD","volume":"149","author":"Bonaca","year":"2024","journal-title":"Circulation"},{"key":"2025011107303453900_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","article-title":"Editor's Choice\u2014European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication","volume":"67","author":"Nordanstig","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2025011107303453900_bib28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0034-1393976","article-title":"Overview of classification systems in peripheral artery disease","volume":"31","author":"Hardman","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"2025011107303453900_bib29","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.2337\/dc24-S010","article-title":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of Care in Diabetes-2024","volume":"47","author":"Nuha Ali","year":"2024","journal-title":"Diabetes Care"},{"key":"2025011107303453900_bib30","first-page":"614","article-title":"Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points","volume":"92","author":"Hiatt","year":"1995","journal-title":"Vasc Clin Trialists Circ"},{"key":"2025011107303453900_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1067\/mva.2002.123092","article-title":"Reproducibility of constant-load treadmill testing with various treadmill protocols and predictability of treadmill test results in patients with intermittent claudication","volume":"36","author":"Degischer","year":"2002","journal-title":"J Vasc Surg"},{"key":"2025011107303453900_bib32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jvs.2013.08.099","article-title":"Vascular Quality of Life Questionnaire-6 facilitates health-related quality of life assessment in peripheral arterial disease","volume":"59","author":"Nordanstig","year":"2014","journal-title":"J Vasc Surg"},{"key":"2025011107303453900_bib33","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","article-title":"Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association","volume":"126","author":"Aboyans","year":"2012","journal-title":"Circulation"},{"key":"2025011107303453900_bib34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.atherosclerosis.2018.01.023","article-title":"Toe-brachial index and exercise test can improve the exploration of peripheral artery disease","volume":"269","author":"Kovacs","year":"2018","journal-title":"Atherosclerosis"},{"key":"2025011107303453900_bib35","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0741-5214(98)70034-5","article-title":"Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease","volume":"28","author":"McDermott","year":"1998","journal-title":"J Vasc Surg"},{"key":"2025011107303453900_bib36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2025011107303453900_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2021.05.003","article-title":"Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial","volume":"78","author":"Bauersachs","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025011107303453900_bib38","doi-asserted-by":"crossref","first-page":"e025504","DOI":"10.1161\/JAHA.122.025504","article-title":"Total cardiovascular and limb events and the impact of polyvascular disease in chronic symptomatic peripheral artery disease","volume":"11","author":"Szarek","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025011107303453900_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025011107303453900_bib40","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2025011107303453900_bib41","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae071\/61228480\/pvae071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/8\/728\/61228480\/pvae071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/8\/728\/61228480\/pvae071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T07:31:04Z","timestamp":1736580664000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/8\/728\/7826783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,10,18]]},"published-print":{"date-parts":[[2025,1,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae071","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,18]]}}}